Validation of Next Generation Cerebral and Tissue Oximeter

• Desaturation (Device), also known as Cerebral and Tissue Oximeter: The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.

Primary outcomes

• Validated the Next Generation Oximeter [Data collected from individual participant over 4 hour timeframe.]: Cerebral overall mean bias (percentage saturation) defined as the average of the differences between the regional saturation (rSO2) value and (fSO2) value obtained from simultaneous arterial and jugular venous blood samples. Cerebral trending is defined as the measurement of changes in regional saturation (rSO2) under conditions of changing fSO2. Cerebral trending mean bias is the average difference between changes in rSO2 values compared against changes in fSO2. Somatic trending mean bias is defined the same as Cerebral trending mean bias except for the location of measurement on the subjects and for Somatic trending mean bias, rS02 was compared to rSO2 on a commercially-available regional oximetry monitor. The smaller value the better performance.

Sex: All, ages: 18 Years to 46 Years, accepts healthy volunteers

Inclusion Criteria:

1. Healthy, male or female subjects between the ages of 18 to ≤46 years;
2. Completion of a health screening for a medical history by a licensed physician, nurse practitioner or physician assistant;
3. Minimum weight 40kg;
4. BMI within range 18.0 - 30.0.

Exclusion Criteria:

1. Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain) \[self-reported\];
2. Prior known severe allergies to medical grade adhesive/tape (Band-Aid) \[self-reported\];
3. Taking any medication other than birth control \[self-reported\];
4. Is currently participating in, or has recently participated in (discontinued within 30 days prior to the hypoxia procedure for this study) in an investigational drug, device, or biologic study \[self-reported\];
5. Has a negative Allen's Test to confirm non-patency of the collateral artery \[clinical assessment by PI or delegate\];
6. Has made a whole blood donation or has had at least 450 ml of blood drawn within 8 weeks prior to the study procedure \[self-reported\];
7. Is female with a positive pregnancy test \[serum or urine\], or is female and is unwilling to use effective birth control between the time of screening and study procedure or is breastfeeding;
8. Has anemia \[lab values specific for gender\];
9. Has a history of sickle cell trait or thalassemia \[self-reported\];
10. Has an abnormal hemoglobin electrophoresis test \[lab measurement\];
11. Has a positive urine cotinine test or urine drug screen or oral ethanol test \[POC testing\];
12. Has a room air saturation less than 95% by pulse oximetry \[measurement by PI or delegate\];
13. Has a clinically significant abnormal ECG \[assessment by PI or delegate\];
14. Has a clinically significant abnormal pulmonary function test via spirometry \[assessment by PI or delegate\];
15. Has a COHb greater than 3%, or MetHb greater than 2% \[measured by venous blood sample co-oximetry\]

Participant flow

Outcome results

• Validated the Next Generation Oximeter (Primary), Mean, Percentage saturation: Desaturation 1.22 +/- 5.92

Adverse events

Time frame: 48 hours post study procedure (desaturation)

Other adverse events by term

• Study Protocol (PDF, 2017-03-15)
• Statistical Analysis Plan (PDF, 2017-07-18)

• Julia Katilius, Study director, Medtronic